2019 American Transplant Congress
“Desens Light”: Single Center Experience Using Rituximab for High Immunologic Risk Kidney Transplant Recipients with Historic DSA
Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, IL
*Purpose: To evaluate the effectiveness of rituximab as induction therapy for pts undergoing kidney transplant (Tx) with historic DSA (hDSA) [Desens. Light].*Methods: 104 consecutive pts…2019 American Transplant Congress
Patients with Immunological Diseases or on Peritoneal Dialysis Are Prone to False Positive Flow Cytometry Cross Match
*Purpose: Despite implementation of virtual cross matches, flow cytometry cross matches (FCXM) are still used by many transplant centers to determine immunological risk prior to…2019 American Transplant Congress
Correlation of Crossmatch Predictions with Actual Results and Clinical Outcomes
1Vanderbilt University Medical Center, Nashville, TN, 2Dialysis Clinic, Inc, Nashville, TN
*Purpose: Flow cytometry crossmatching (FXM) is recognized as a valuable tool to assess immunological risk prior to renal transplantation. The increased resolution in HLA typing…2019 American Transplant Congress
Anti-Complement Component 5 Antibody Based Immunosuppression Induced Accommodation in ABO Incompatible Heart Transplantation
*Purpose: Plasmapheresis in combination with immunoglobulin and rituximab is often used to induce accommodation in ABO-incompatible (ABOi) living-donor transplantation; however, this regimen cannot be applied…2019 American Transplant Congress
Post-Transplant Cancer Following Living Donor HLA-Incompatible Kidney Transplantation
1Johns Hopkins University, Baltimore, MD, 2University of Alabama, Birmingham, AL
*Purpose: Incompatible living donor kidney transplantation (ILDKT) recipients require increased immunosuppression compared to their compatible living donor kidney transplant (CLDKT) counterparts. This continued exposure to…2019 American Transplant Congress
Towards Human Leukocyte Antigen Immunogenicity Assessment at the Individual Patient Level
*Purpose: Allorecognition of donor HLA and induction of humoral alloimmunity is a major cause of graft loss after solid-organ transplantation. Current approaches to study molecular…2019 American Transplant Congress
Emergence of Anti-HLA Antibodies after Catch-Up Vaccinations in Pediatric Kidney Transplant Candidates
*Purpose: Evaluate anti-HLA antibody (Ab) emergence after catch-up vaccinations in pediatric kidney transplant candidates (PKTC).*Methods: A single center retrospective review of PKTC 25% from baseline,…2019 American Transplant Congress
The Effect Of Exclusive Virtual Crossmatch To Allocate Deceased Donor Kidney Transplant On Cold Ischemia Time And Acute Rejection
*Purpose: Virtual crossmatch (VXM) using Luminex single antigen bead has significantly improved prediction of an actual negative crossmatch. A negative crossmatch is typically required for…2019 American Transplant Congress
Center-Level Variation in HLA-Incompatible Living Donor Kidney Transplantation Outcomes
1Johns Hopkins University, Baltimore, MD, 2University of Alabama School of Medicine, Birmingham, AL
*Purpose: Desensitization protocols for HLA-incompatible living donor kidney transplantation (ILDKT) vary across centers. The impact of these variations, as well as other practice variations, on…2018 American Transplant Congress
Rituximab Interference in B-Cell Crossmatch: A Problem Solved
Background: Rituximab is commonly prescribed in ABO- or HLA-incompatible kidney transplantation. When used before transplant it interferes with B lymphocyte complement-dependent crossmatch (CDC CM) or…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 9
- Next Page »